RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07874282, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Histopathologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC not amenable to curative-intent therapy

    Inclusion criterion 6

  3. Female study participants must be post-menopausal, surgically sterilized, or, if of child-bearing potential, have a negative serum pregnancy test within 7 days prior to the first dose, agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment, and refrain from oocyte donation and breastfeeding during this period; male study participants must agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment and refrain from sperm donation during this period

    Inclusion criterion 11

    Received thoracic radiotherapy >30 Gy within 6 months prior to randomization; palliative local therapy for non-target lesions within 2 weeks prior to randomization; non-specific immunomodulatory therapy within 2 weeks prior to the first dose of study drug; or traditional Chinese herbal/proprietary medicine with anti-neoplastic indications within 1 week prior to randomization

    Exclusion criterion 5

    Prior systemic anti-neoplastic therapies other than chemotherapy and PD-1/PD-L1 antibodies

    Exclusion criterion 7

    For subjects previously exposed to PD-1/PD-L1 inhibitors: prior occurrence of immune-related adverse events (irAEs) Grade 3 or higher due to immunotherapy, irAEs leading to permanent treatment discontinuation, Grade 2 immune-related cardiac toxicity, or any-grade neurological or ocular irAEs; prior adverse events requiring immunosuppressive agents other than corticosteroids, or recurrent adverse events during prior immunotherapy requiring re-initiation of systemic corticosteroid therapy

    Exclusion criterion 14

    Other malignancy diagnosed within 3 years prior to initiation of study drug administration

    Exclusion criterion 26

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    Inclusion criterion 5

  5. Availability of c-Met expression, PD-L1 expression and driver gene test results including at minimum EGFR and ALK for enrollment

    Inclusion criterion 9

  6. At least one measurable non-cerebral lesion per RECIST v1.1

    Inclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07874282, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily agrees to participate in the study and provides signed informed consent
  • Willing and able to comply with study and follow-up procedures
  • Male or female, aged 18-80 years
  • Expected survival≥3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histopathologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC not amenable to curative-intent therapy
  • No prior systemic anti-neoplastic therapy for advanced or metastatic non-squamous NSCLC
  • At least one measurable non-cerebral lesion per RECIST v1.1
  • Availability of c-Met expression, PD-L1 expression and driver gene test results including at minimum EGFR and ALK for enrollment
  • Adequate cardiac, bone-marrow, hepatic, renal and coagulation function meeting relevant criteria
  • Female study participants must be post-menopausal, surgically sterilized, or, if of child-bearing potential, have a negative serum pregnancy test within 7 days prior to the first dose, agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment, and refrain from oocyte donation and breastfeeding during this period; male study participants must agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment and refrain from sperm donation during this period

Exclusion Criteria:

  • Histologically confirmed presence of any squamous NSCLC, small-cell carcinoma, neuroendocrine carcinoma, or sarcoma component
  • Known positive driver gene or gene mutations with approved first-line treatment options
  • Presence of active brain metastases
  • Screening-period imaging shows obvious tumor necrosis or cavitation, with bleeding risk upon study entry as judged by the investigator
  • Received thoracic radiotherapy >30 Gy within 6 months prior to randomization; palliative local therapy for non-target lesions within 2 weeks prior to randomization; non-specific immunomodulatory therapy within 2 weeks prior to the first dose of study drug; or traditional Chinese herbal/proprietary medicine with anti-neoplastic indications within 1 week prior to randomization
  • Prior immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune-cell therapy, or any other therapies targeting tumor immune mechanisms
  • Prior systemic anti-neoplastic therapies other than chemotherapy and PD-1/PD-L1 antibodies
  • Systemic treatment with corticosteroids or other immunosuppressive medications within 2 weeks prior to randomization
  • Administration of any live or live-attenuated vaccine within 4 weeks prior to randomization, or planned administration of any live or live-attenuated vaccine during the study
  • Participation in another clinical trial within 4 weeks prior to randomization
  • Major surgery, interventional therapy, or severe trauma within 4 weeks prior to randomization, or planned major surgery during the study period; core-needle biopsy or other minor surgery within 7 days prior to the first dose
  • History of severe coagulation disorders; or subjects receiving anticoagulant therapy, excluding prophylactic-dose anticoagulants such as low-molecular-weight heparin
  • Toxicities from prior anti-neoplastic therapy not recovered to Grade 0-1 as defined by CTCAE v6.0; except for alopecia, pigmentation, expected irrecoverable endocrinopathies from prior immunotherapy that are stably controlled with medication, and other conditions assessed by the investigator not interfering with study drug treatment
  • For subjects previously exposed to PD-1/PD-L1 inhibitors: prior occurrence of immune-related adverse events (irAEs) Grade 3 or higher due to immunotherapy, irAEs leading to permanent treatment discontinuation, Grade 2 immune-related cardiac toxicity, or any-grade neurological or ocular irAEs; prior adverse events requiring immunosuppressive agents other than corticosteroids, or recurrent adverse events during prior immunotherapy requiring re-initiation of systemic corticosteroid therapy
  • Presence of severe acute or chronic infection
  • Hemoptysis, active gastrointestinal bleeding, peptic ulcer, epistaxis, or other bleeding events requiring intervention within 4 weeks prior to randomization; or severe esophagogastric varices, vasculitis, vascular ulcer, aneurysm, or vascular dissection judged by the investigator to carry a high bleeding risk
  • Severe arterial/venous thromboembolic events or cerebrovascular accident within 6 months prior to the first dose
  • Active or clinically significant cardiac disease
  • History of interstitial lung disease or pulmonary inflammation requiring systemic steroid therapy; or chest-CT at screening showing any evidence of active ILD/pulmonary inflammation, idiopathic pulmonary fibrosis, organizing pneumonia, treatment-induced pneumonitis, idiopathic pneumonia, radiation pneumonitis, severe impaired pulmonary function, or acute exacerbation of chronic obstructive pulmonary disease within 1 month prior to randomization
  • History of gastrointestinal perforation and/or fistula, or gastrointestinal obstruction within 6 months prior to randomization
  • Presence of systemic diseases that are not stably controlled as judged by the investigator
  • Active autoimmune disease, or prior history of autoimmune disease with potential for recurrence
  • Subjects with a history of other acquired or congenital immunodeficiency diseases, or history of organ transplantation
  • Known hypersensitivity or delayed-type allergic reaction to any components of the study drug or analogous medicinal products
  • Clinically symptomatic third-space effusion or third-space effusion requiring intervention
  • Other malignancy diagnosed within 3 years prior to initiation of study drug administration
  • Poor compliance; subjects expected to be unable to cooperate with completion of trial procedures
  • Any other past or present disease, abnormal physical finding, or laboratory abnormality, in the investigator's opinion, rendering the subject unsuitable for study drug administration, likely to confound interpretation of study results, or placing the subject at high-risk
  • Local or systemic disease not caused by malignancy, or diseases/symptoms secondary to the tumor, that may result in substantial medical risk and/or uncertainty in survival-time assessment, such as manifestations of cachexia

Quoted from ClinicalTrials.gov, NCT07874282, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07874282, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07874282